Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Am Acad Dermatol. 2020 Jul 2;83(6):1674–1680. doi: 10.1016/j.jaad.2020.06.998

Table 2:

Clinical characteristics of patients with prior authorizations

Primary associated diagnosis Patients (n = 48)
n (%)
Dermatomyositis/suspected dermatomyositis 25 (52)
Lupus 13 (27)
Overlapping (lupus vs. dermatomyositis, lupus/rheumatoid arthritis overlap, 4 (8)
dermatomyositis and morphea)
Bullous pemphigoid 2 (4)
Psoriasis 1 (2)
Granuloma annulare 1 (2)
Rosacea 1 (2)
Vitiligo 1 (2)
Medication Prescriptions or Orders Placed (n = 51)
n (%)
Topicals (tacrolimus ointment, pimecrolimus, clobetasol, fluocinolone triamcinolone) 21 (41)
Mychophenolate/Mycophenolic acid 12 (24)
Biologics (tofacitinib, omalizumab, secukinumab) 4 (8)
Lenalidomide 2 (4)
Methotrexate 2 (4)
Azathioprine 1 (2)
Imaging (MRI/CT/echocardiogram) 9 (18)